Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Table 6 Median dose and relative confidential interval values of gemcitabine alone and in combination with EGFR/HER2 pathway inhibitors on BTC cell lines.

Dm μM (confidence interval)	TFK-1	CI*	EGI-1	CI*	HuH28	CI*	TGBC1-TKB	CI*
Gemcitabine (Gem)	0.1		0.00074		> 10		0.28
	(0.003-2.93)		(0.0002-0.002)				(0.12-0.43)
Gem + erlotinib	0.04	0.11	0.00017	0.56	> 10	0.5	0.24	0.8
	(0.03-0.73)		(0.00006-0.0005)				(0.033-2.28)
Gem + gefitinib	0.08	0.15	0.00004	0.15	2.9	0.9	0.26	0.9
	(1.1-2.9)		(0.0000007-0.002)		(0.15-5.3)		(0.13-0.53)
Gem + lapatinib	0.07	0.36	0.03		2.01	1.5	0.13	0.6
	(0.09-29.01)		(0.006-0.17)		(0.46-8.6)		(0.06-0.27)
Gem + sorafenib	0.07	0.017	0.01	0.19	> 10		0.11	0.062
	(0.000009-0.31)		0.00019-1.07)				(0.05-0.23)
Gem + everolimus	0.03	0.15	0.00057	0.015	> 10		0.001	0.07
	0.004-0.43)		(0.00002-0.01)				(0.00007-0.022)

ISSN: 1471-2407